#	Pagina
attuale pagina	/open-h2020/projects/208156/index.html

Opendata, web and dolomites

LentiFactory

MAGIC (MAnufacturing of Gene delivery tools for Industrial and Clinical applications)

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

LentiFactory project word cloud

Explore the words cloud of the LentiFactory project. It provides you a very rough idea of what is the project "LentiFactory" about.

class rna platforms accelerating powerful changing transform combine stem game provider editing mainly tools infrastructure vectalys broad edge cutting stage lentiviral regulatory manufacturing platform carriers property develops rare requiring producing expression cell 2005 trials lv industrial bioprocessing strategies transient diseases market lentiflash generation therapy grade patented clinical purity founded lf technologies synthetic engineering vector thanks collaborative world quality expertise stable deep untreated customers clear car immunotherapy thereby parallel highest technological gene capacity biology ing lack lives biotech primary cells severe therapeutic integrating genetic company extensive vectors gmp cancers committed intellectual proprietary move patients

Project "LentiFactory" data sheet

The following table provides information about the project.

Coordinator	FLASH THERAPEUTICS Organization address address: CANAL BIOTECH II - 3 RUE DES SATELLITES city: TOULOUSE postcode: 31400 website: www.vectalys.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	https://www.vectalys.com/news/news-details/28-03-2017/lentifactory-horizon-2020-sme-instrument-phase-i-414
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2017
Duration (year-month-day)	from 2017-03-01 to 2017-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FLASH THERAPEUTICS FLASH THERAPEUTICS Organization address address: CANAL BIOTECH II - 3 RUE DES SATELLITES city: TOULOUSE postcode: 31400 website: www.vectalys.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (TOULOUSE)	coordinator	50˙000.00

Map

Project objective

Founded in 2005, Vectalys is a biotech company that develops world leading gene delivery technologies for industrial and therapeutic applications. Vectalys has built a state-of-the-art proprietary lentiviral vectors (LV) production platform to provide its customers and partners with the highest quality of LV. Based on 10 years of collaborative research, the resulting LV purity is now recognized as a key success factor for cutting-edge stable cell engineering on primary and stem cells. In parallel, thanks to its deep understanding of market needs, Vectalys has developed and patented a game-changing class of RNA carriers called LentiFlash (LF), a new generation of non-integrating LV dedicated to gene-editing applications requiring a transient expression.

Bioprocessing know-how, stable and transient delivery tools and intellectual property combine into a unique and powerful integrated platform capable of accelerating both gene-editing and immunotherapy applications. Based on recent results of early CAR-T cells clinical trials, mainly in the US, the market will now need an extensive scale-up capacity to produce GMP-grade LV and LF. The application potential is significant and includes both clinical approaches (gene therapy, gene-editing, and immunotherapy) and industrial systems (synthetic biology, modelling development).

Compared to the US, there is in Europe a clear lack of clinical manufacturing infrastructure and of integrated platforms that include both research and GMP production, thereby offering a broad expertise from vector design to therapeutic strategies. From a non-regulatory pre-clinical stage market, Vectalys has the capacity to move forward into the clinical stage market as a GMP grade value provider. The company has taken the technological lead in this field in Europe and is now committed to producing these tools at a clinical grade in order to transform the lives of patients with severe genetic and rare diseases as well as untreated cancers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LENTIFACTORY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LENTIFACTORY" are provided by the European Opendata Portal: CORDIS opendata.